Back to News
Market Impact: 0.12
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Can-Fite BioPharma said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma. The update does not include efficacy, safety, or timeline specifics, so near-term read-through for outcomes appears limited.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
CANF0.05
More News
- Alibaba shares jump as new AI chip, data center buildout plans unveiled
- Steve Jobs made Apple iconic. Tim Cook made it a $5 trillion behemoth
- Alibaba Cloud plans six-year stroll to 20GW of datacenters, reveals chip to power them
- VusionGroup shares jump 8% on strong H1 profit growth, tariff relief
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow